Mandibular gingival carcinoma (including central mandibular carcinoma) Mandibular gingival carcinoma, Central mandibular carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria Patients who meet all of the following criteria will be eligible for this study: 1. Patients with mandibular gingival carcinoma (in cluding central mandibular carcinoma) who requir e surgical treatment based on the Clinical Practice Guidelines for Oral Cancer. 2. Patients aged 20 years or older and younger th an 75 years at the time of obtaining informed cons ent. 3. Patients with a performance status of 0-1. 4. Patients from whom written informed consent f or participation in this study can be obtained.
Exclusion criteria
Exclusion criteria: Exclusion Criteria Patients who meet any of the following criteria will be excluded from the study: 1. Patients who are pregnant, breastfeeding, or possibly pregnant. 2. Patients judged to be inappropriate for particip ation by the principal investigator or sub-investiga tors. 3. Patients whose scheduled surgery date is less t han 7 days after providing informed consent for this study. 4. Patients with hypersensitivity to the components of the investigational drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fluciclovine PET uptake in mandibular gingival carcinoma (including central mandibular carcinoma) | — |
Secondary
| Measure | Time frame |
|---|---|
| If uptake in the tumour is confirmed, the following will be evaluated: - Comparison of tumour uptake extent with FDG PET images - Numerical comparison using semi-quantitative parameters (SUV parameters) - Comparison between the resected pathological specimen volume and uptake on fluciclovine PET/CT or FDG PET/CT | — |
Countries
Japan, Not applicable
Contacts
Gunma University Hospital